Sign in

    Qize Ding

    Research Analyst at Redburn Atlantic

    Qize Ding is an Analyst specializing in biotechnology and pharmaceutical equities at Redburn Atlantic, where he covers major companies such as Legend Biotech and Genmab. Notably, he initiated coverage of Legend Biotech with a Buy rating and projected significant upside, with documented calls returning as high as 181.97% and earning a 92.47% upside rating on Genmab from TipRanks, reflecting strong performance in investment recommendations. Ding joined Redburn Atlantic in 2024 and is recognized for data-driven ratings and successful stock selection in the healthcare sector, with earlier career details and professional licenses not publicly disclosed. His analytical expertise is evidenced by high-accuracy calls and a focus on growth-oriented biopharma stocks.

    Qize Ding's questions to GENMAB (GMAB) leadership

    Qize Ding's questions to GENMAB (GMAB) leadership • Q2 2025

    Question

    Qize Ding from Redburn Atlantic asked for more detail on the planned RINA S trial in non-small cell lung cancer, specifically the line of therapy and whether it would be tested as a monotherapy or in combination.

    Answer

    Citing the competitive landscape, Chief Medical Officer Tahamtan Ahmadi declined to provide specific details but confirmed the study is designed to explore RINA S as both a monotherapy and in combination therapy. He suggested the company's past development strategies offer a clue to the approach.

    Ask Fintool Equity Research AI

    Qize Ding's questions to GENMAB (GMAB) leadership • Q2 2025

    Question

    Qize Ding from Redburn Atlantic asked for follow-up details on the RINA S Phase II trial in non-small cell lung cancer, specifically whether it would target first or second-line settings and test RINA S as a monotherapy or in combination.

    Answer

    Tahamtan Ahmadi, EVP & Chief Medical Officer, responded cautiously due to the competitive landscape. He confirmed the study is designed with the optionality to test RINA S both as a monotherapy and in combination, suggesting that Genmab's established development philosophy provides a guide to the likely strategic approach.

    Ask Fintool Equity Research AI